Import and Export Licensing of Investigational Products in Chinese Clinical Trials

Introduction

Investigational products (IPs) are the backbone of clinical trials, requiring strict oversight to ensure patient safety, data integrity, and regulatory compliance. In China, the import and export of investigational products are regulated under the National Medical Products Administration (NMPA) framework, with additional oversight from customs authorities and the Ministry of Commerce. Sponsors must secure specific licenses and follow rigorous documentation processes before trial materials can be shipped into or out of China. These requirements affect not only multinational sponsors importing drugs for use in Chinese trials but also domestic companies exporting investigational products for global programs. This article explores the regulatory framework, licensing procedures, operational challenges, and best practices for managing import and export of IPs in China.

Background and Regulatory Framework

NMPA Oversight of Investigational Products

The NMPA regulates investigational products under the Drug Administration Law (2019) and related regulations. All IPs must meet Good Manufacturing Practice (GMP) standards, and import/export is permitted only with valid licenses issued by the NMPA and customs authorities.

Customs and Ministry of Commerce Role

In addition to NMPA approval, customs clearance is required for each shipment. The Ministry of Commerce issues permits for import/export of restricted substances, including biologics and controlled drugs. Delays often occur when documentation is incomplete or inconsistent.

Case Example: Oncology IMP Import

A multinational sponsor importing an oncology IP faced delays when customs identified inconsistencies between the shipping invoice and the NMPA import license. The issue required resubmission of corrected documents, delaying trial initiation by three months.

Core Clinical Trial Insights

Import Licensing Process

To import IPs, sponsors must:
Submit an application to the NMPA including protocol, product specifications, and GMP certificates
Obtain an import drug license (IDL) or trial-specific import permit
Provide customs with translated documentation, invoices, and certificates
Ensure that shipment packaging complies with GSP (Good Supply Practice) standards
The process typically takes 2–3 months but may be expedited for priority trials.

Export Licensing for Multinational Programs

For trials requiring export of biological samples or investigational products, sponsors must obtain export permits from the NMPA and Ministry of Commerce. Special rules apply to human genetic materials, overseen by the Human Genetic Resources Administration of China (HGRAC). Unauthorized export can result in severe penalties.

Documentation Requirements

Sponsors must maintain detailed records including:
Import/export licenses issued by NMPA
GMP compliance certificates
Clinical trial approval letters
Shipping invoices and customs declarations
Temperature monitoring records for cold-chain products
Lack of accurate documentation is a common cause of customs delays.

Role of CROs and Logistics Vendors

CROs and specialized logistics vendors manage the complex process of securing permits, preparing documentation, and ensuring compliance with GSP. Partnering with experienced vendors minimizes risks of shipment delays or regulatory non-compliance.

Data Localization and Cross-Border Transfers

For IP-related data, China’s data localization laws require that clinical trial data be stored domestically. Export of data for global submissions requires regulatory approval, further complicating multinational trial logistics.

Best Practices & Preventive Measures

Sponsors should:
Begin licensing applications well in advance of trial initiation
Engage CROs and logistics vendors with China-specific expertise
Verify accuracy of all documentation before shipment
Train site staff on customs clearance and chain-of-custody requirements
Build contingency timelines for potential delays
These preventive measures ensure timely trial initiation and compliance with regulatory expectations.

Scientific & Regulatory Evidence

NMPA regulations on IP import/export align with ICH E6(R2) GCP and WHO guidelines for investigational product management. Comparative evidence shows China’s requirements are more stringent than those of FDA and EMA due to additional customs and HGRAC oversight. The 2019 Drug Administration Law provides the legal foundation for enforcement.

Special Considerations

Biologics, controlled substances, and cell/gene therapies face additional scrutiny, requiring specialized permits and cold-chain logistics. Rare disease trials often involve small batches of imported IPs, necessitating precise documentation and monitoring. Sponsors must anticipate these complexities in trial planning.

When Sponsors Should Seek Regulatory Advice

Sponsors should consult the NMPA during trial planning, particularly for biologics, gene therapies, or trials requiring export of human samples. Early regulatory engagement clarifies requirements and reduces risks of customs delays or non-compliance penalties.

Case Studies

Case Study 1: Vaccine Import for MRCT

A vaccine sponsor secured NMPA import permits and customs clearance within eight weeks by engaging an experienced logistics vendor. The streamlined process allowed the MRCT to start on schedule, demonstrating the value of proactive planning.

Case Study 2: Export of Biological Samples

A rare disease sponsor required export of biological samples for genomic analysis abroad. With HGRAC approval and Ministry of Commerce permits, the sponsor successfully shipped samples while maintaining compliance with data localization laws.

FAQs

1. What licenses are required to import investigational products into China?

Sponsors need an NMPA-issued import permit or IDL, customs clearance, and supporting documentation such as GMP certificates.

2. How long does the import licensing process take?

Typically 2–3 months, though timelines may vary depending on product type and trial priority status.

3. What are the challenges of exporting investigational products or samples?

Export requires NMPA and Ministry of Commerce permits, and HGRAC approval for genetic materials, making it complex and time-consuming.

4. Can CROs manage import/export processes?

Yes, CROs and logistics vendors often manage licensing, documentation, and customs clearance on behalf of sponsors.

5. What happens if shipments lack proper documentation?

Shipments may be delayed, rejected at customs, or lead to regulatory penalties for non-compliance.

6. Do China’s rules align with global practices?

Yes, though China imposes additional oversight, particularly for biologics and genetic materials, compared with FDA or EMA frameworks.

Conclusion & Call-to-Action

Import and export licensing of investigational products in China is a complex but essential component of clinical trial operations. By understanding NMPA requirements, engaging experienced CROs and logistics partners, and planning early, sponsors can avoid costly delays and ensure compliance. Organizations conducting trials in China should treat IP supply chain management as a strategic priority to safeguard trial continuity and accelerate global development.